Advances in Prostate Cancer Therapeutics
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 October 2025 | Viewed by 123
Special Issue Editor
Interests: function and regulation of TGF-beta expression and signaling in prostate and renal cancers; androgen receptor signaling; cross-talk of TGF-beta with IGF-I, AKT, mTOR, androgen receptor, and Hic-5; survivin in cancer; Notch/Jagged1 signaling; drug discovery; YM155; mTOR inhibitors; TGF-beta signaling inhibitors; apoptosis; hypoxia and hypoxia-inducible pathways; AMPKs; chemoprevention; polyphenols
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer (PCa), the second most frequently diagnosed malignancy in men, is a leading cause of cancer mortality worldwide. Although localized PCa is often managed effectively with surgery and radiation therapy, metastatic PCa presents significant therapeutic challenges. Androgen deprivation therapy (ADT) remains the cornerstone of treatment; nonetheless, resistance frequently develops, leading to castration-resistant PCa (CRPC). The past decade has seen remarkable advancement in therapeutic strategies, including next-generation androgen receptor signaling inhibitors, poly(ADP-ribose) polymerase (PARP) inhibitors, radiotherapies, immunotherapies, and combination regimens. Despite such progress, treatment resistance, biomarker-driven patient selection, and the optimal sequencing of therapies remain critical areas of ongoing research.
This Special Issue of Pharmaceuticals seeks to highlight the latest developments in PCa therapeutics, with a focus on novel drug discovery, mechanisms of resistance, biomarkers for treatment response, and personalized medicine approaches. We invite original articles, reviews, and preclinical and clinical studies that explore cutting-edge treatment strategies, translational research, and emerging therapeutic modalities aimed at improving patient outcomes.
Researchers, clinicians, and industry experts are encouraged to submit their work to this Special Issue. For further details, please visit www.mdpi.com.
Dr. David Danielpour
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- androgen deprivation therapy (ADT)
- castration-resistant prostate cancer (CRPC)
- androgen receptor signaling inhibitors
- PARP inhibitors
- ionizing radiation therapy
- radiopharmaceuticals
- immunotherapy
- biomarkers
- personalized medicine
- therapeutic resistance
- targeted therapy
- combination therapy
- hormone-sensitive prostate cancer (HSPC)
- next-generation therapeutics
- translational oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
